Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium.
Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium.
复制标题
DOI：
10.1158/2159-8290.cd-13-0219
复制
发表时间：
2013-10
期刊：
影响因子：
28.2
通讯作者：
Clinical Proteomic Tumor Analysis Consortium (CPTAC)
中科院分区：
文献类型：
--
作者：
Ellis MJ;Gillette M;Carr SA;Paulovich AG;Smith RD;Rodland KK;Townsend RR;Kinsinger C;Mesri M;Rodriguez H;Liebler DC;Clinical Proteomic Tumor Analysis Consortium (CPTAC)
美国国家癌症研究所（NCI）临床蛋白质组肿瘤分析联盟（CPTAC）正在将最新一代的蛋白质组技术应用于癌症基因组图谱（TCGA）计划中的基因组注释肿瘤，该计划是NCI和国家人类基因组研究所的联合倡议。通过提供个体肿瘤中DNA，RNA和蛋白质异常的完全整合的核算，这些数据集将阐明基因组异常与癌症表型之间的复杂关系，从而产生生物学见解以及一系列新的候选生物标志物和治疗靶点，这些候选生物标志物和治疗靶点可以使用靶向质谱法进行验证。
The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) is applying latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of the NCI and National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biological insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verification using targeted mass spectrometry methods.